Indian drugmaker JB Chem posts first-quarter profit jump on strong domestic demand

J B Chemicals and Pharmaceuticals

30/07/2025 15:39

July 30 (Reuters) - Indian drugmaker JB Chemicals & Pharmaceuticals JBCH.NS reported an 8.9% higher first-quarter profit on Wednesday, led by healthy domestic demand for its drugs.

The maker of "Rantac" antacid reported a consolidated net profit of 2.02 billion rupees ($23.02 million) for the quarter ended June 30, compared with 1.77 billion rupees a year earlier.

Its overall revenue climbed 14.5% to 10.94 billion rupees, boosted by demand in its key domestic formulations business.

KEY CONTEXT

The Indian pharmaceutical market grew 8% in June, led by drugs treating chronic conditions such as hypertension and diabetes, benefitting drugmakers specialising in such treatments.

JB Chem's revenue from its chronic and acute portfolios surged 15% and 12%, respectively, while an 8% climb in its contract drug manufacturing business also aided its results.

PEER COMPARISON

Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Revenue growth (%)
Profit growth (%)
Mean rating*
# of analysts
Stock to price target**
J B Chemicals and Pharmaceuticals Ltd
JBCH.NS
31.99
20.99
12.41
18.95
Buy
12
0.87
Glenmark Pharmaceuticals Ltd
GLEN.NS
32.30
19.29
12.66
27.16
Buy
9
0.99
Torrent Pharmaceuticals Ltd
TORP.NS
46.35
27.76
12.48
25.42
Buy
29
0.99
Mankind Pharma Ltd
MNKI.NS
46.66
27.87
18.00
13.98
Buy
15
0.96

  * The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
 ** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

APRIL TO JUNE STOCK PERFORMANCE

 -- All data from LSEG

($1 = 87.7400 Indian rupees)

GSK India's Q1 stock performance vs peers https://reut.rs/3H8pVnN

 (Reporting by Aleef Jahan and Kashish Tandon in Bengaluru; Editing by Vijay Kishore)

 ((Kashish.Tandon@thomsonreuters.com; 8800437922;))